BNF:

6.1.2.3

Status:

Do Not Prescribe (DNP), Red, Green

Decision Date:

July 2016

Comments

Prescribe by brand.

Liraglutide (Zegluxen):

• GREEN: Preferred 1st line daily GLP1 (1.2mg daily).  See local guidance for supporting material for prescribers.
• MHRA alert (January 2024) - Shortage of GLP-1 receptor agonists (GLP-1 RA) update

Liraglutide (Saxenda):

• RED: NICE TA664 - Liraglutide (Saxenda) for managing overweight and obesity. Prescribe by brand. Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, but it is restricted to prescribing in secondary care by a specialist multidisciplinary tier 3 weight management service with a commercial agreement in place. (Decision date - January 2021)
• DNP: NICE TA749 – Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (Decision date - February 2022)

 

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again